Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Abbott's earnings call highlights strong financial performance, with high single-digit sales growth and double-digit EPS growth. The company is optimistic about future growth, driven by new product developments and market opportunities. Despite some headwinds, such as reduced COVID testing sales and challenges in China, Abbott is strategically positioned for continued success. The positive sentiment from analysts during the Q&A session reinforces this outlook, particularly in diabetes, CRM, and biosimilars. Overall, the sentiment leans positive, with potential for stock price appreciation in the near term.
Key Financial Performance
Sales Growth (excluding COVID testing sales) 7.5% in Q2 2025, 8% in the first half of 2025. Reasons: Exclusion of COVID testing sales and strong demand across various markets.
Adjusted Earnings Per Share (EPS) $1.26 in Q2 2025, reflecting 11% growth year-over-year and 16% sequential growth from Q1 2025. Reasons: Strong sales performance and operational efficiencies.
Nutrition Sales 3.5% growth in Q2 2025. Reasons: 6.5% growth in Adult Nutrition driven by strong demand for Ensure and Glucerna brands, catering to protein-rich diets and diabetes management.
Diagnostics Sales Declined 1.5% in Q2 2025. Reasons: Year-over-year decline in COVID testing sales and volume-based procurement programs in China. Excluding China, Core Lab Diagnostics grew 8%.
EPD (Established Pharmaceuticals Division) Sales Nearly 8% growth in Q2 2025. Reasons: Strong performance in key 15 markets (India, China, Asia, Latin America, Middle East) driven by favorable healthcare trends and demand for branded generic medicines.
Medical Devices Sales 12% growth in Q2 2025. Reasons: Double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management. Specific drivers include 19.5% growth in continuous glucose monitors and strong adoption of innovative technologies like MitraClip and AVEIR leadless pacemaker.
Adjusted Gross Margin 57% of sales in Q2 2025, increased by 100 basis points year-over-year. Reasons: Operational efficiencies and favorable foreign exchange impact.
Adjusted Operating Margin 22.9% of sales in Q2 2025, increased by 100 basis points year-over-year. Reasons: Improved cost management and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Adult Nutrition: Sales increased by 3.5% in the quarter, driven by 6.5% growth in Adult Nutrition. Strong demand for Ensure and Glucerna brands globally, driven by consumers seeking complete and balanced nutrition, especially for protein-rich diets and diabetes management.
Medical Devices: Sales grew 12%, driven by double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management. Continuous glucose monitors sales reached $1.9 billion, growing 19.5%. New product launches include Volt PFA catheter, next-generation MitraClip, and Tendyne mitral replacement valve.
EPD (Established Pharmaceuticals Division): Sales increased nearly 8%, surpassing $1 billion in quarterly sales for the first time in key 15 markets, including India, China, and others in Asia, Latin America, and the Middle East. Growth supported by favorable demographic trends and demand for branded generic medicines.
Margin Expansion: Achieved over 100 basis points of margin expansion in both gross and operating margins in the first half of 2025.
Earnings Growth: Adjusted earnings per share grew 11% year-over-year in Q2 2025, exceeding consensus estimates.
Biosimilars Portfolio: Completed 10 regulatory approval submissions across emerging markets, with launches projected to begin in 2026.
Mitral Valve Replacement: FDA approval of Tendyne mitral replacement valve and progress on transfemoral mitral valve replacement product, with pivotal trial planned for next year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Diagnostics: Sales declined 1.5% in the quarter due to a year-over-year decline in COVID testing sales and the impact of volume-based procurement programs in China. These factors represent a projected headwind of around $700 million or 750 basis points on the full year 2025 sales growth in Diagnostics.
China Market: Volume-based procurement programs in China negatively impacted sales in Diagnostics, contributing to a significant headwind for the company's overall sales growth.
Foreign Exchange: While foreign exchange had a favorable impact in the second quarter, fluctuations in currency exchange rates remain a potential risk to financial performance.
Regulatory Approvals: The company is awaiting regulatory approvals for biosimilars in emerging markets, with launches projected to begin in 2026. Delays or denials in these approvals could impact future growth plans.
Medical Devices: Growth in Medical Devices is heavily reliant on the success of new product launches and regulatory approvals, such as the Tendyne mitral replacement valve and the AVEIR leadless pacemaker. Any delays or issues in these areas could hinder growth.
Economic and Competitive Factors: Economic uncertainties and competitive pressures in key markets, including India, China, and Latin America, could impact the performance of branded generic medicines and other product lines.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Projected headwind in Diagnostics: Sales in Diagnostics are expected to face a projected headwind of around $700 million or 750 basis points on the full year 2025 sales growth due to the year-over-year decline in COVID testing sales and the impact of volume-based procurement programs in China.
Biosimilars Launch: Abbott plans to launch biosimilars in emerging markets starting in 2026, following the completion of 10 regulatory approval submissions.
Diabetes Care Growth: Sales of continuous glucose monitors are projected to continue growing, with $1.9 billion in sales in the second quarter and a growth rate of 19.5%.
Mitral Valve Replacement Technology: Abbott plans to start the pivotal trial for its new Transfemoral mitral valve replacement product next year, following FDA breakthrough designation.
AVEIR Leadless Pacemaker: Abbott is targeting to start the pivotal trial for the AVEIR conduction system pacing next year, following successful feasibility study outcomes.
Heart Failure Business Growth: The heart failure business is expected to continue its growth trajectory, driven by balanced growth across the portfolio, including double-digit growth in ventricular assist devices and CardioMEMS.
Third Quarter Earnings Forecast: Abbott forecasts adjusted earnings per share for the third quarter to be in the range of $1.28 to $1.32.
Long-term Growth Objectives: Abbott aims to achieve high single-digit growth, healthy margin expansion, and double-digit EPS growth in the long term.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide context for Abbott's 2025 performance and the headwinds affecting growth this year?
A:Robert B. Ford explained that Abbott's goal is to ensure reliable and sustainable growth across its diverse portfolio. He highlighted strong growth in the device business (12% in the first half), pharma (8%), and nutrition (5%). However, headwinds include a drop in COVID testing sales, challenges in the China core lab market, and reduced U.S. foreign aid funding for HIV testing, amounting to over $1 billion in headwinds. Despite this, Abbott is forecasting high single-digit growth and double-digit EPS growth for 2025.
Q:Could the growth rate accelerate into 2026 as headwinds reverse?
A:Robert B. Ford acknowledged the possibility of growth rate acceleration in 2026 as headwinds reverse. He mentioned opportunities across the portfolio, including electrophysiology, which has consistently exceeded expectations. However, he noted it is too early to make definitive statements.
Q:What trends are you seeing in the diabetes and electrophysiology (EP) product lines?
A:Robert B. Ford reported strong performance in diabetes, with U.S. Libre growing 26% and international acceleration. Key growth drivers include intensive insulin users, basal segment, and non-insulin users. The Dual-analyte sensor is expected to significantly impact the CGM market. In EP, double-digit growth was observed, with a focus on rolling out Volt internationally. Early feedback on Volt has been excellent, with benefits like reduced procedure time and muscle contraction.
Q:What is Abbott's reaction to the proposed competitive bidding for CGM and RFK Jr.'s comments on wearables?
A:Robert B. Ford stated that competitive bidding would involve DMEs, not CGM manufacturers, and is unlikely to impact Abbott. Regarding RFK Jr.'s comments, he emphasized the benefits of wearables for behavior modification and health improvement, aligning with Abbott's mission. He also expressed support for initiatives promoting health and wellness.
Q:How is Abbott's CRM business performing, and what is the outlook?
A:Robert B. Ford highlighted strong growth in the CRM business, with growth rates increasing from 7% in 2023 to 10% this quarter. The AVEIR product has fundamentally changed the growth trajectory, with increased physician training and implants. Abbott plans to launch a next-generation AVEIR with longer battery life and expand internationally.
Q:What are the offsets in the EPS guidance despite operating margin tweaks and organic growth adjustments?
A:Philip P. Boudreau explained that offsets include reduced FX headwinds and tariff impacts, with tariffs expected to be under $200 million. FX remains a year-over-year headwind but less than historical averages. These factors help maintain the EPS guidance midpoint.
Q:What is Abbott's approach to M&A in diagnostics and MedTech?
A:Robert B. Ford stated that Abbott is selective in M&A, focusing on strategic fits that generate attractive returns. The company is not looking to acquire businesses solely to increase top-line revenue but prioritizes profitability and ROIC.
Q:What is the outlook for Abbott's Structural Heart business, particularly Amulet?
A:Robert B. Ford expressed optimism about the Structural Heart business, highlighting Amulet's potential growth with upcoming trial readouts and second-generation device improvements. He emphasized the importance of data to support market expansion and the competitive positioning of Abbott's products.
Q:What are Abbott's expectations for the TAVR franchise?
A:Robert B. Ford noted positive feedback for Navitor, with sales doubling over two years, driven by international growth. Abbott is expanding its U.S. presence by doubling its team and expects label expansion and market disruption to drive growth. A next-generation balloon-expandable TAVR is in development.
Q:What is the status of the Dual-analyte sensor and its potential impact?
A:Robert B. Ford did not provide specific launch timing or pricing details but emphasized the sensor's potential to transform the CGM market. Abbott has completed clinical trials and is working with insulin pump companies to ensure quick integration upon approval.
Q:What is Abbott's strategy for biosimilars?
A:Robert B. Ford outlined a strategy to leverage existing infrastructure to bring biosimilars to emerging markets. The focus is on autoimmune diseases, women's health, oncology, and GLP-1s. Abbott plans to launch in small markets this year and expand next year, with biosimilars contributing to growth in the coming years.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the launch timing and pricing strategy for the Dual-analyte sensor, as well as the exact impact of tariffs and FX on EPS guidance. Additionally, they did not disclose specific M&A targets or the timeline for the next-generation TAVR launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amulet MitraClip
BTIG LLC
Bank PLC
Bank Research
Barclays Bank
BofA Securities
Boudreau
Co Research
Diagnostics
LLC Research
Nutrition
Research Division
care provider
class
conduction system
contribution
development valve
digit sale
health care
integration
market launch
market world
medicine
milestone
number
objective digit
outcome
pacing
procedure
provider patient
rhythm
solution
study
technology FDA
uptake
valve disease
valve repair
valve replacement
ABT Transcript
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript
Positive4-16
The earnings call shows strong growth in key segments like Electrophysiology and Heart Failure, supported by product innovations and international expansion. Despite some challenges in CGM and Nutrition, the company has a diversified portfolio and strategic plans for growth. The Q&A reveals a cautious but optimistic outlook, with management addressing concerns and highlighting opportunities in underpenetrated markets. Overall, the positive growth drivers and strategic focus outweigh the conservative guidance, leading to a positive sentiment.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Positive1-22
Abbott's earnings call reflects strong financial performance with double-digit EPS growth and improved margins. Despite slightly lower revenue growth guidance, the company anticipates recovery in the Nutrition segment and sustained growth across other divisions. Positive product developments, particularly in Medical Devices and Diagnostics, coupled with strategic initiatives, bolster a positive outlook. The Q&A session reveals confidence in overcoming short-term challenges and executing long-term growth strategies, contributing to an overall positive sentiment.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Positive10-15
The earnings call summary and Q&A indicate strong growth prospects in diabetes care and heart failure, with positive developments in new product launches like the dual-analyte sensor and AVEIR pacemaker. Despite headwinds in diagnostics and China's market, the company's strategic focus on innovation and expansion in high-growth segments like Structural Heart and EP suggest a positive outlook. However, the lack of detailed guidance on CMS coverage and tariff impacts introduces some uncertainty, but overall, the sentiment leans towards a positive stock price movement.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Positive7-17
Abbott's earnings call highlights strong financial performance, with high single-digit sales growth and double-digit EPS growth. The company is optimistic about future growth, driven by new product developments and market opportunities. Despite some headwinds, such as reduced COVID testing sales and challenges in China, Abbott is strategically positioned for continued success. The positive sentiment from analysts during the Q&A session reinforces this outlook, particularly in diabetes, CRM, and biosimilars. Overall, the sentiment leans positive, with potential for stock price appreciation in the near term.
ABT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
